Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually

NEW YORK--(BUSINESS WIRE)-- #FDA--Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.

Full Story →